Thursday, February 11, 2010 (Last Updated: 02/12/2010)
THURSDAY, Feb. 11 (HealthDay News) -- Denosumab, an antibody that targets cells involved in bone destruction, is the first systemic treatment shown to be effective in treating giant-cell tumor, a rare osteolytic tumor that can metastasize to the lung, according to a study published online Feb. 10 in The Lancet Oncology.
As part of an open-label, phase 2 study, David Thomas, of the Peter MacCallum Cancer Centre in East Melbourne, Australia, and colleagues treated 37 patients with recurrent or unresectable giant-cell tumor with 120 mg subcutaneous denosumab every 28 days, with loading doses on days eight and 15 of the first month.
At 25 weeks, the researchers found that 86 percent of 35 evaluable patients, including some who had lung lesions, had a tumor response, as defined by elimination of at least 90 percent of giant cells or no radiological progression of the target lesion. In addition, 84 percent of 31 patients evaluated for clinical benefit had reduced pain or improved functional status, and 29 percent had bone repair. Five patients had grade 3 to 5 adverse events, one of which could be linked to the treatment.
"To our knowledge, this is the first report that clearly shows a promising systemic treatment option for this rare type of tumor," write the authors of an accompanying editorial.
The study was supported by Amgen. Authors of the study reported financial relationships with the pharmaceutical industry, including Amgen.
Diabetes & Endocrinology
Copyright © 2010 HealthDay. All rights reserved.